Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy

Junko Tanizaki, MD, PhD; Hiroaki Kuroda, MD, PhD; Toshihide Yokoyama, MD; Makoto Takahama, MD, PhD; Hiroyasu Shoda, MD, PhD; Atsushi Nakamura, MD, PhD; Yoshitaka Kitamura, MD, PhD; Nobuaki Mamesaya, MD, PhD; Yoshihisa Kadota, MD, PhD; Kenji Sawa, MD, PhD; Kyoichi Okishio, MD, PhD; Morihito Okada, MD, PhD; Chihiro Suminaka, MS; Kenta Noda, PhD; Kazuko Sakai, PhD; Yasutaka Chiba, PhD; Kazuto Nishio, MD, PhD; Kenji Chamoto, PhD; Tasuku Honjo, MD, PhD; Nobuyuki Yamamoto, MD, PhD; Kazuhiko Nakagawa, MD, PhD; Hidetoshi Hayashi, MD, PhD

JTO Clinical and Research Reports (Dec 2023)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy

Junko Tanizaki, MD, PhD,
Hiroaki Kuroda, MD, PhD,
Toshihide Yokoyama, MD,
Makoto Takahama, MD, PhD,
Hiroyasu Shoda, MD, PhD,
Atsushi Nakamura, MD, PhD,
Yoshitaka Kitamura, MD, PhD,
Nobuaki Mamesaya, MD, PhD,
Yoshihisa Kadota, MD, PhD,
Kenji Sawa, MD, PhD,
Kyoichi Okishio, MD, PhD,
Morihito Okada, MD, PhD,
Chihiro Suminaka, MS,
Kenta Noda, PhD,
Kazuko Sakai, PhD,
Yasutaka Chiba, PhD,
Kazuto Nishio, MD, PhD,
Kenji Chamoto, PhD,
Tasuku Honjo, MD, PhD,
Nobuyuki Yamamoto, MD, PhD,
Kazuhiko Nakagawa, MD, PhD,
Hidetoshi Hayashi, MD, PhD

Affiliations

Junko Tanizaki, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan; Corresponding author. Address for correspondence: Junko Tanizaki MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan.
Hiroaki Kuroda, MD, PhD: Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
Toshihide Yokoyama, MD: Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan
Makoto Takahama, MD, PhD: Department of General Thoracic Surgery, Osaka City General Hospital, Osaka, Japan
Hiroyasu Shoda, MD, PhD: Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
Atsushi Nakamura, MD, PhD: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
Yoshitaka Kitamura, MD, PhD: Division of Chest Surgery, Hyogo Cancer Center, Akashi, Japan
Nobuaki Mamesaya, MD, PhD: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Yoshihisa Kadota, MD, PhD: Department of General Thoracic Surgery, Osaka Habikino Medical Center, Osaka, Japan
Kenji Sawa, MD, PhD: Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
Kyoichi Okishio, MD, PhD: Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan
Morihito Okada, MD, PhD: Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
Chihiro Suminaka, MS: Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
Kenta Noda, PhD: Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
Kazuko Sakai, PhD: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan
Yasutaka Chiba, PhD: Clinical Research Center, Kindai University Hospital, Osaka, Japan
Kazuto Nishio, MD, PhD: Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan
Kenji Chamoto, PhD: Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Immuno-Oncology PDT, Kyoto University Graduate School of Medicine, Kyoto, Japan
Tasuku Honjo, MD, PhD: Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Nobuyuki Yamamoto, MD, PhD: Internal Medicine III, Wakayama Medical University, Wakayama, Japan
Kazuhiko Nakagawa, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
Hidetoshi Hayashi, MD, PhD: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan

Journal volume & issue: Vol. 4, no. 12
p. 100590

Abstract

Read online

Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these curable disease stages. Methods: This study (WJOG12319LTR) was designed as a biomarker study to evaluate whether soluble immune markers were prognostic or predictive on relapse-free survival in patients with stage II to IIIA NSCLC who underwent complete resection and adjuvant chemotherapy with cisplatin plus S-1, which is an oral fluoropyrimidine formulation that consists of tegafur, gimeracil, and oteracil, or S-1 alone in the previous WJOG4107 study. Archived plasma samples were assayed for soluble (s) forms of programmed cell death protein 1 (sPD-1), programmed death-ligand 1(sPD-L1), and CTLA-4 (sCTLA-4) with the highly sensitive HISCL system. Using time-dependent receiver operating characteristic curve analysis, the area under the curves were derived and optimal cutoff values were determined. Using the cutoff values, whether the marker was prognostic or predictive was assessed by survival analysis. Results: A total of 150 patients were included in the study. The time-dependent receiver operating characteristics analysis revealed that the area under the curves for sPD-1, sPD-L1, and sCTLA-4 were 0.54, 0.51, and 0.58, respectively. The survival analysis did not reject that hazard ratios were 1 in terms of the soluble immune marker and the treatment-marker interaction for all three markers. Conclusions: There was no proof that circulating concentrations of sPD-1, sPD-L1, and sCTLA-4 were prognostic or predictive factors of the outcome for adjuvant chemotherapy after complete resection in patients with NSCLC.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords